Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
---|---|---|---|---|---|---|---|---|---|
Delpazolid 그람양성균 |
-일반 결핵 -다제내성 결핵 -MRSA / VRE -NTM |
|
- Orphan Drug |
||||||
|
- L/O for China |
Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
---|
Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
---|---|---|---|---|---|---|---|---|---|
LCB02-0133 Nokxaban,FXa Inhibitor |
|
L/O for global (Profit Sharing) |
|||||||
|
Sub L/O for China |
Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
---|---|---|---|---|---|---|---|---|---|
LCB39 LBG-STING agonist |
|
- I/O Targeted |
|||||||
LCB33 ENPP1 inhibitor |
|
-Combi with ADCs |